Skip to main content
. 2020 Feb 3;12(2):126. doi: 10.3390/pharmaceutics12020126
CAT3 13a-(S)-3-pivaloyloxyl-6,7-dimethoxyphenanthro(9,10-b)-indolizidine
PF403 13a-(S)-3-hydroxyl-6,7-dimethoxyphenanthro(9,10-b)-indolizidine
GBM Glioblastoma multiforme
TMZ Temozolomide
SLN Solid lipid nanoparticles
MDCK-MDR1 Madin-Darby canine kidney cells transfected with the human MDR1 gene
SD Sprague-Dawley
NMR Nuclear magnetic resonance
TMS Tetramethylsilane
DL Drug loading
EE Encapsulation efficiency
OA Oleic acid
OA-CAT3 Oleic acid and CAT3 conjugate
OA-CAT3-SLN OA-CAT3 loaded SLN
CAT3-SLN With the same composition and contents to the OA-CAT3-SLN except the preparation of OA-CAT3 in advance
DSC Differential scanning calorimetry
FTIR Fourier transform infrared spectroscopy
API Active pharmaceutical ingredient
PVDF Polyvinylidene fluoride
TEER Transepithelial electrical resistance
DI Deionized
PDI Polydispersity index
HBSS Hanks’ balanced salt solution
AP Apical side
BL Basolateral
LC-MS/MS Liquid chromatography-mass spectrometry
P app Apparent permeability coefficient
HPLC High-performance liquid chromatography
C6-luc Luciferase-expressing C6 cells
DAPI 4′,6-diamidino-2-phenylindole
LSCM laser scanning confocal microscopy
MTT 3-(4, 5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide
MCYP Methyl-β-Cyclodextrin
PBS Phosphate-buffered saline
Cou-6 Fluorescent Coumarin 6
ISTD Internal standard
DAS Drug and Statistics